Mederi Therapeutics announced that it raised $18.5 million in Series B funding.
The Series B funding is comprised of preferred stock and venture debt.
Mederi Therapeutics manufactures and markets medical devices that use radiofrequency energy to treat digestive system diseases. The Series B funding will be used to support the use of Mederi's Stretta therapy for gastroesophageal reflux disease and Secca therapy for bowel incontinence.
Reducing Supply Chain Costs
First Navio Unicondylar Knee Replacement Performed in France
Abrams Royal Pharmacy Issues Voluntary Recall on All Unexpired Sterile Products
The Series B funding is comprised of preferred stock and venture debt.
Mederi Therapeutics manufactures and markets medical devices that use radiofrequency energy to treat digestive system diseases. The Series B funding will be used to support the use of Mederi's Stretta therapy for gastroesophageal reflux disease and Secca therapy for bowel incontinence.
More Articles on Supply Chain:
Reducing Supply Chain Costs
First Navio Unicondylar Knee Replacement Performed in France
Abrams Royal Pharmacy Issues Voluntary Recall on All Unexpired Sterile Products